Atara is a biotechnology company focused on combining cutting edge science with natural human biology to transform the treatment of difficult-to-treat cancers and autoimmune conditions, including multiple sclerosis (MS). By harnessing the power and compelling biological features of T cells –the immune system's most effective weapon in fighting disease –to target Epstein-Barr virus (EBV), Atara is working to deliver targeted cell-based innovation in the form of next-generation allogeneic T-cell immunotherapies.
Jakob Dupont, MD, Head of Global Research & Development at Atara, will discuss the recent landmark studies and evidence showing EBV as the leading cause of MS. He will detail Atara's ATA188, a first-of-its-kind T-cell immunotherapy that specifically targets EBV-infected immune cells, currently in a Phase 2 clinical study called "EMBOLD" with a primary data readout on-track for October 2023.
Dr. Dupont will also summarize the data that led to the recent European approval of the first-ever allogeneic T-cell immunotherapy, EbvalloTM (tabelecleucel), and how Atara is taking this EBV technology to the next level by modifying the EBV T cells with a chimeric antigen receptor (CAR) to create CAR T-cell therapies that can target solid tumors and other hematological malignancies.